Results 91 to 100 of about 33,513 (195)

Biphasic effects of losartan potassium on immobility in mice [PDF]

, 2005
The effects of losartan potassium, an angiotensin AT, receptor blocker on immobility in forced swim test have been studied. Effect of losartan potassium, nortriptyline HCl, fluoxetine, HCl and reserpine per se and in combination on forced swimming ...
Vijayapandi, P., Nagappa, A.N.
core   +1 more source

Angiotensin‐converting enzyme and exercise adaptations: Genetic variability, pharmacological modulation and future directions

The Journal of Physiology, EarlyView.
Abstract figure legend ACE I/D genotype, enzyme activity and integrated physiological adaptations. Upper panel: Conceptual framework linking the ACE I/D polymorphism (left) with circulating/tissue ACE activity (centre; violin plots based on hypothetical data for illustration) and strength/power versus endurance phenotypes (right).
Tórur Sjúrðarson, Nikolai B. Nordsborg   +1 more
wiley   +1 more source

Western blots comparing losartan and water groups.

, 2015
Immunoblots for pERK1/2, ERK1/2, pSmad2, pSmad3, Smad2/3 and GAPDH for 12 scleral specimen groups. (1) water control; (2) losartan control; (3) fellow eyes of water-treated glaucoma; (4) fellow eyes of losartan-treated glaucoma; (5) water-treated ...
Thao D. Nguyen (695816), Derek S. Welsbie (818782), Harry A. Quigley (695817), Matthew R. Steinhart (818783), Ian F. Pitha (818781), Ericka N. Oglesby (818785), Elizabeth C. Kimball (818789), Cathy Nguyen (116527), Jessica Kim (52077), Cynthia A. Berlinicke (818786), Mary Ellen Pease (818784), Joan J. Jefferys (818788), Katherine L. Mitchell (818787)   +12 more
core   +1 more source

Angiotensin II receptor blocker losartan exacerbates muscle damage and exhibits weak blood pressure-lowering activity in a dysferlin-null model of Limb-Girdle muscular dystrophy type 2B.

PLoS ONE, 2019
There is no cure or beneficial management option for Limb-Girdle muscular dystrophy (MD) type 2B (LGMD2B). Losartan, a blood pressure (BP) lowering angiotensin II (AngII) receptor type 1 (ATR1) blocker (ARB) with unique anti-transforming growth factor-β (
Zoe White, Nadia Milad, Arash Y Tehrani, William Wei-Han Chen, Graham Donen, Stephanie L Sellers, Pascal Bernatchez   +6 more
doaj   +1 more source

Maternal nutrition as a key determinant of placental and developing blood–brain barrier xenobiotic protective functions

The Journal of Physiology, EarlyView.
Abstract figure legend Suboptimal maternal nutrition alters placental and developing blood–brain barrier (BBB) protective function and is associated with increased fetal brain vulnerability. In the placenta, nutritional adversity may reduce the exchange surface area and promote meta‐inflammation, compromising barrier efficiency in a model‐ and context ...
Kristin L. Connor, Nycolle I. S. Souza, Bruno G. Anjos, Stephen G. Matthews, Enrrico Bloise   +4 more
wiley   +1 more source

Immune cells in the pathogenesis of abdominal aortic aneurysm: Roles, regulation and targeted interventions

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
This review provides a comprehensive overview of how macrophages, neutrophils, T cells and other immune cells infiltrate the aortic wall, undergo phenotypic shifts and interact with one another in abdominal aortic aneurysm (AAA). Background Abdominal aortic aneurysm (AAA) is a lethal degenerative vascular disease with no approved clinical drugs. Immune
Junqi Peng, Hanqing Zhang, Yun Wu, Song Chen   +3 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Agonists and the Incidence of Atrial Fibrillation in Obese Patients With Heart Failure With Preserved Ejection Fraction and No Diabetes

Journal of Arrhythmia, Volume 42, Issue 5, October 2026.
Among obese, non‐diabetic patients with HFpEF, GLP‐1 RA therapy was not significantly associated with incident atrial fibrillation but was associated with lower all‐cause mortality. Prospective studies are needed to clarify the potential role of GLP‐1 RAs in AF prevention. ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) reduce
Farah Rassam, Esteban Kosak Lopez, Sarah Sass, Thitiphan Srikulmontri, Evan Isaacs, John Malin, Phuuwadith Wattanachayakul, Olayinka Afolabi‐Brown   +7 more
wiley   +1 more source

Losartan Rescues Inflammation-related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis. [PDF]

Am J Respir Crit Care Med, 2020
Kim MD, Baumlin N, Yoshida M, Polineni D, Salathe SF, David JK, Peloquin CA, Wanner A, Dennis JS, Sailland J, Whitney P, Horrigan FT, Sabater JR, Abraham WM, Salathe M.   +14 more
europepmc   +1 more source

Chronic treatment with Losartan and cerebral ischemic tolerance.

, 2009
Clinical trials have suggested that Losartan has beneficial effects on preventing stroke beyond its antihypertensive properties. Although there is evidence for Losartan reducing ischemic damage following a highly localized type of stroke, its role in ...
Zhao, Zonghang, Tuor, Ursula I., Barber, Phil   +2 more
core   +1 more source

Modeling the Influence of CYP2C9 and ABCB1 Gene Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Losartan

Pharmaceutics
Background/Objectives: Hypertension is a pathological condition characterized by elevated systolic and/or diastolic blood pressure. A range of pharmacotherapeutic agents are available to treat this condition and prevent complications, including the ...
Dmitry Babaev, Elena Kutumova, Fedor Kolpakov   +2 more
doaj   +1 more source